PTAB.US: Decisions of PTAB Patent Trial and Appeal Board Updated Daily.

Wednesday, August 13, 2014

merck2, susi

custom search

Tech Center 2800 Semiconductors, Electrical and Optical Systems and Components
2875 Ex Parte Hong et al 11511423 - (D) NAGUMO 103 MORGAN LEWIS & BOCKIUS LLP (WA) DZIERZYNSKI, EVAN P

Tech Center 1700 Chemical & Materials Engineering
1711 Ex Parte Wochner et al 12674299 - (D) ROESEL 103 BROOKS KUSHMAN P.C. DUNLAP, CAITLIN NOELLE DENNI

The fact that Wochner also discloses many other possible combinations of acids does not support nonobviousness. Merck & Co., Inc. v. Biocraft Labs., Inc., 874 F.2d 804, 807 (Fed. Cir. 1989) (that reference “discloses a multitude of effective combinations does not render any particular formulation less obvious,” especially where “the claimed composition is used for the identical purpose taught by the prior art”); In re Susi, 440 F.2d 442, 445 (CCPA 1971) (obviousness rejection affirmed where the disclosure of the prior art was “huge, but it undeniably include[d] at least some of the compounds recited in appellant’s generic claims and [was] of a class of chemicals to be used for the same purpose as appellant’s additives”).

Merck & Co. v. Biocraft Laboratories, 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir. 1989) 716.02(a) 2123 2144.05 2144.08

Susi, In re, 440 F.2d 442, 169 USPQ 423 (CCPA 1971) 2123 2144.08

Tech Center 2800 Semiconductors, Electrical and Optical Systems and Components
2859 Ex Parte Harris 12552238 - (D) GARRIS 103 Law Office of Scott C Harris, Inc RAMADAN, RAMY O

Tech Center 3700 Mechanical Engineering, Manufacturing, and Products & Design
3769 Ex Parte Kilborn et al 11386038 - (D) FREDMAN 103 37 C.F.R. § 41.50(b) 103 Nellcor Puritan Bennett LLC SORIANO, BOBBY GILES

No comments :